Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

iTeos Therapeutics announced that the GALAXIES Lung-201 Phase 2 trial, assessing the combination of belrestotug and dostarlimab for lung cancer, did not meet the criteria for clinically meaningful ...

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...